Literature DB >> 24423658

Cerebrolysin attenuates cerebral and hepatic injury due to lipopolysaccharide in rats.

O M E Abdel-Salam1, E A Omara, N A Mohammed, E R Youness, Y A Khadrawy, A A Sleem.   

Abstract

This study aimed to investigate the effect of cerebrolysin on oxidative stress in the brain and liver during systemic inflammation. Rats were intraperitoneally challenged with a single subseptic dose of lipopolysaccharide (LPS; 300 μg/kg) without or with cerebrolysin at doses of 21.5, 43 or 86 mg/kg. After 4 h, rats were euthanized and the brain and liver tissues were subjected to biochemical and histopathological analyses. Cerebrolysin revealed inhibitory effects on the elevation of lipid peroxidation and nitric oxide induced by LPS. In contrast, the decrease in reduced glutathione level and paraoxonase activity induced by LPS was attenuated by an injection of cerebrolysin in a dose-dependent manner. Moreover, cerebrolysin reduced LPS-induced activation of brain NF-κB and reversed LPS-induced decline of brain butyrylcholinesterase and acetylcholinesterase activities in a dose-dependent manner. Histopathological analyses revealed that neuronal damage and liver necrosis induced by LPS were ameliorated by cerebrolysin dose-dependently. Cerebrolysin treatment dose-dependently attenuated LPS-induced expressions in cyclooxygenase 2, inducible nitric oxide synthase, and caspase-3 in the cortex or striatum as well as the liver. These results suggest that cerebrolysin treatment might have beneficial therapeutic effects in cerebral inflammation. Cerebrolysin might also prove of value in liver disease and this possibility requires further exploration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24423658     DOI: 10.5582/ddt.2013.v7.6.261

Source DB:  PubMed          Journal:  Drug Discov Ther        ISSN: 1881-7831


  1 in total

1.  LPS-induced impairment of Na+/K+-ATPase activity: ameliorative effect of tannic acid in mice.

Authors:  Karina Pereira Luduvico; Luiza Spohr; Mayara Sandrielly Soares de Aguiar; Fernanda Cardoso Teixeira; Natália Pontes Bona; Julia Eisenhardt de Mello; Roselia Maria Spanevello; Francieli Moro Stefanello
Journal:  Metab Brain Dis       Date:  2022-06-27       Impact factor: 3.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.